The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Lets hope it leads to a SP breakout as this tight range seems hard to break.
In my mind very undervalued.
GL.
On the Brand agreement shouldn't be very far away!
Lets hope for a stonker of an RNS!
GL.
Fingers crossed seller has done and we have an orderly market.
GL.
the key point here is opening a revenue stream after all the research and development costs.
and when they do they do it with a global giant and even sell their ****!!!!
gl.
Tell that to someone with kidney disease!
Shud make them feel better?
GL.
Sadly I preferred it when I was on my own!
GL.
Got some more!
GL.
Have been in here a long time.
This company has developed tests that will bring in millions.
Buy and hold.
GL.
There are two key rules when investing in smallcaps. Firstly 'buy when there’s blood on the streets', & secondly ‘skate to where the puck is heading’.
Both of these apply to expert immunodiagnostics firm Verici Dx (Mrkcap £10m), who today announced a potentially break-through global licensing partnership with healthcare giant Thermo Fisher Scientific (Mrkcap $177bn) to exclusively develop an assay for pre-transplant kidney testing.
Here house broker Singer Capital Markets reckons the deal refers to Clarava. #VRCI’s 1st-in-class, blood test that allows doctors to identify those patients (pre graft) most likely to require increased monitoring - including adjustments in the type, dose & duration of immunosuppressants. Especially important when handling deceased donor parts which provide >60% of all organs.
Elsewhere the agreement also grants Thermo Fisher the sole right (but not obligation) to manufacture, distribute & sell the prognostic worldwide. Alongside providing it with access to a portion of #VRCI’s proprietary urine samples – further highlighting the value stored within its treasure trove of research assets.
In return Verici Dx will receive an upfront fee, augmented by staged payments dependent on operational deliverables (eg tech transfer & publications). Which in aggregate (assuming things go to plan) should equate to c.$5m over the next year with further instalments & ongoing royalties thereafter.
So what does this mean?
Well to me, the agreement not only represents another major endorsement of Verici Dx’s top notch science by an industry behemoth. But also the anticipated $5m should extend #VRCI’s cash run-way until at least the end of 2024 (source Singer Capital Markets), reduce costs and provide the Board with the option of perhaps moving deeper into this type of science-rich, capital-lite licensing model.
Which if adopted, would leverage the sales forces & supply chains of similar 3rd parties. Whilst equally enabling #VRCI to focus entirely on its unique IPR to drive better patient outcomes & material shareholder value.
In fact, this hypothetical arrangement would not be too dis-similar to Bioventix’s already successful licensing model, that is used to commercialise its monoclonal antibodies across the diagnostic sector.
CEO Sara Barrington commenting: “We are incredibly proud of our advancements in transforming potential outcomes for kidney transplant patients. By collaborating with Thermo Fisher Scientific, we believe we can accelerate the development of our technology, helping ensure that it reaches those who need it the most.”
Finally wrt the financials, Singer Capital Markets have replaced the revenues previously anticipated from Clarava with the above licensing fees.
As such FY23 turnover is now forecast to come in at $0.3m, climbing to $8.6m in 2024 (vs $4.9m B4) & generating an adjusted EBITDA of $0.1m, while ending Dec'23 with net cash of $0.1m. Plus they have a BUY
Very illiquid share so SP movements are very volatile!
Strap in LOL.
GL.
Were fully funded until mid 2024 before this JV.
Thermo Fisher are huge!
Start of the revenue streams.
No placings ahoy!
GL.
Wow Thermo Fisher revenue in 2021 was over $39 billion.!
What a partner and vote of confidence!
GL.
NT to buy!
GL.
This has to be proof of the business model revenue streams.
Rerate in progress!
GL.